Shp2 in myocytes is essential for cardiovascular and neointima development

Bautch, 2015, Blood and lymphatic vessel formation, Cold Spring Harb. Perspect. Biol., 7, a008268, 10.1101/cshperspect.a008268 Langlois, 2010, Conditional inactivation of TGF-beta type II receptor in smooth muscle cells and epicardium causes lethal aortic and cardiac defects, Transgenic Res., 19, 1069, 10.1007/s11248-010-9379-4 Mazurek, 2017, Vascular cells in blood Vessel Wall development and disease, Adv. Pharmacol., 78, 323, 10.1016/bs.apha.2016.08.001 Lacolley, 2017, Vascular smooth muscle cells and arterial stiffening: relevance in development, aging, and disease, Physiol. Rev., 97, 1555, 10.1152/physrev.00003.2017 Akhirome, 2017, The complex genetic basis of congenital heart defects, Circ. J., 81, 629, 10.1253/circj.CJ-16-1343 Feng, 1999, Shp-2 tyrosine phosphatase: signaling one cell or many, Exp. Cell Res., 253, 47, 10.1006/excr.1999.4668 Neel, 2003, The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling, Trends Biochem. Sci., 28, 284, 10.1016/S0968-0004(03)00091-4 Dance, 2008, The molecular functions of Shp2 in the Ras/mitogen-activated protein kinase (ERK1/2) pathway, Cell. Signal., 20, 453, 10.1016/j.cellsig.2007.10.002 Tartaglia, 2001, Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome, Nat. Genet., 29, 465, 10.1038/ng772 Digilio, 2002, Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene, Am. J. Hum. Genet., 71, 389, 10.1086/341528 Nakamura, 2007, Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome, J. Clin. Invest., 117, 2123, 10.1172/JCI30756 Schramm, 2012, The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling, Am. J. Physiol. Heart Circ. Physiol., 302, H231, 10.1152/ajpheart.00665.2011 Adachi, 1997, Predominant expression of the src homology 2-containing tyrosine phosphatase protein SHP2 in vascular smooth muscle cells, Virchows Arch., 430, 321, 10.1007/BF01092755 Grinnell, 2010, Role of protein tyrosine phosphatase SHP2 in barrier function of pulmonary endothelium, Am. J. Physiol. Lung Cell Mol. Physiol., 298, L361, 10.1152/ajplung.00374.2009 Zhang, 2019, SHP2 protects endothelial cell barrier through suppressing VE-cadherin internalization regulated by MET-ARF1, FASEB J., 33, 1124, 10.1096/fj.201800284R Seki, 2002, Role of SRC homology 2-containing tyrosine phosphatase 2 on proliferation of rat smooth muscle cells, Arterioscler. Thromb. Vasc. Biol., 22, 1081, 10.1161/01.ATV.0000022878.37277.EC Kiyan, 2009, The tyrosine phosphatase SHP-2 controls urokinase-dependent signaling and functions in human vascular smooth muscle cells, Exp. Cell Res., 315, 1029, 10.1016/j.yexcr.2008.12.011 Courboulin, 2011, Role for miR-204 in human pulmonary arterial hypertension, J. Exp. Med., 208, 535, 10.1084/jem.20101812 Tao, 2014, Myeloid-specific disruption of tyrosine phosphatase Shp2 promotes alternative activation of macrophages and predisposes mice to pulmonary fibrosis, J. Immunol., 193, 2801, 10.4049/jimmunol.1303463 Zhang, 2012, Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis, FASEB J., 26, 2338, 10.1096/fj.11-200139 Kumar, 1997, Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow, Arterioscler. Thromb. Vasc. Biol., 17, 2238, 10.1161/01.ATV.17.10.2238 Ross, 1971, The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers, J. Cell Biol., 50, 172, 10.1083/jcb.50.1.172 Yang, 2006, An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival, Dev. Cell, 10, 317, 10.1016/j.devcel.2006.01.002 Turner, 2015, alpha5 and alphav integrins cooperate to regulate vascular smooth muscle and neural crest functions in vivo, Development., 142, 797, 10.1242/dev.117572 Majesky, 2017, Differentiated smooth muscle cells generate a subpopulation of resident vascular progenitor cells in the adventitia regulated by Klf4, Circ. Res., 120, 296, 10.1161/CIRCRESAHA.116.309322 Li, 1996, SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis, Circ. Res., 78, 188, 10.1161/01.RES.78.2.188 Wang, 2014, Deletion of yes-associated protein (YAP) specifically in cardiac and vascular smooth muscle cells reveals a crucial role for YAP in mouse cardiovascular development, Circ. Res., 114, 957, 10.1161/CIRCRESAHA.114.303411 Chen, 2016, Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases, Nature., 535, 148, 10.1038/nature18621 Li, 2018, Genetic lineage tracing of nonmyocyte population by dual recombinases, Circulation., 138, 793, 10.1161/CIRCULATIONAHA.118.034250 Kontaridis, 2008, Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways, Circulation., 117, 1423, 10.1161/CIRCULATIONAHA.107.728865 Princen, 2009, Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death, Mol. Cell. Biol., 29, 378, 10.1128/MCB.01661-08 Owens, 2004, Molecular regulation of vascular smooth muscle cell differentiation in development and disease, Physiol. Rev., 84, 767, 10.1152/physrev.00041.2003 Xu, 2017, Macrophage-restricted Shp2 tyrosine phosphatase acts as a rheostat for MMP12 through TGF-beta activation in the prevention of age-related emphysema in mice, J. Immunol., 199, 2323, 10.4049/jimmunol.1601696 Newby, 2006, Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates, Cardiovasc. Res., 69, 614, 10.1016/j.cardiores.2005.08.002 Xu, 2014, Vascular wall extracellular matrix proteins and vascular diseases, Biochim. Biophys. Acta, 1842, 2106, 10.1016/j.bbadis.2014.07.008 Langdon, 2007, SHP-2 is required for the maintenance of cardiac progenitors, Development., 134, 4119, 10.1242/dev.009290 Lauriol, 2015, The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease, Semin. Cell Dev. Biol., 37, 73, 10.1016/j.semcdb.2014.09.013 Ganesan, 1997, Noonan syndrome and moyamoya, Pediatr. Neurol., 16, 256, 10.1016/S0887-8994(97)89980-8 Joyce, 2016, The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome. Joyce S et al., Eur. J. Hum. Genet., 24, 690, 10.1038/ejhg.2015.175 Roberts, 2013, Noonan syndrome, Lancet., 381, 333, 10.1016/S0140-6736(12)61023-X Myllyharju, 2001, Collagens and collagen-related diseases, Ann. Med., 33, 7, 10.3109/07853890109002055 Archer, 2010, Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies, Circulation., 121, 2045, 10.1161/CIRCULATIONAHA.108.847707 Cheng, 2018, Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats, BMC Pulm Med., 18, 130, 10.1186/s12890-018-0700-y Wright, 2000, Protein-tyrosine phosphatases in the vessel wall: differential expression after acute arterial injury, Arterioscler. Thromb. Vasc. Biol., 20, 1189, 10.1161/01.ATV.20.5.1189 Li, 2014, SHP2 positively regulates TGFbeta1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1, J. Biol. Chem., 289, 34152, 10.1074/jbc.M113.546077 Zehender, 2018, The tyrosine phosphatase SHP2 controls TGFbeta-induced STAT3 signaling to regulate fibroblast activation and fibrosis, Nat. Commun., 9, 3259, 10.1038/s41467-018-05768-3 Xie, 2013, Smad2 and myocardin-related transcription factor B cooperatively regulate vascular smooth muscle differentiation from neural crest cells, Circ. Res., 113, e76, 10.1161/CIRCRESAHA.113.301921 Mao, 2012, Vascular smooth muscle cell Smad4 gene is important for mouse vascular development, Arterioscler. Thromb. Vasc. Biol., 32, 2171, 10.1161/ATVBAHA.112.253872